Work ongoing on election-delayed DAMA:
This article was originally published in Clinica
The German competent authority, BfArM, which oversees pharmaceutical product registration and materio- and pharmacovigilance, has been restructured in what is seen as the first phase of changes ahead of its eventual transformation into an agency, called DAMA. The new German pharmaceutical and medical products agency, whose passage into law has, however, been delayed by the SPD's early election call, will have a high level of autonomy and a modern management structure with which to set policy for the E23bn pharmaceutical and E20bn medical technology sectors, said temporary institute head Professor Reinhard Kurth. A law enacting DAMA will have to await the next legislative period.
You may also be interested in...
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.
HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.